Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2006
Business Overview: McKesson is a Fortune 16 corporation providing supply, information, and care management products and services to the healthcare industry. Operations are conducted through three segments: Pharmaceutical Solutions (95% of revenue), Medical-Surgical Solutions, and Provider Technologies.
Key Financial Metrics
| Metric (in millions) | Fiscal 2006 | Fiscal 2005 | Fiscal 2004 |
|---|---|---|---|
| Revenues | $88,050 | $80,120 | $69,210 |
| Gross Profit | $3,862 | $3,450 | $3,235 |
| Net Income (Loss) | $751 | $(157) | $647 |
| Diluted EPS | $2.38 | $(0.53) | $2.19 |
| Operating Cash Flow | $2,744 | $1,538 | $595 |
| Total Debt | $991 | $1,211 | $1,485 |
| Cash and Equivalents | $2,142 | $1,800 | $708 |
| Working Capital | $3,404 | $3,570 | $3,616 |
Segment Performance (2006): Pharmaceutical Solutions generated $83.4 billion in revenue with $1.211 billion in operating profit. Medical-Surgical Solutions generated $3.1 billion in revenue with $70 million in operating profit. Provider Technologies generated $1.5 billion in revenue with $143 million in operating profit.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 10% to $88.1 billion, driven primarily by the Pharmaceutical Solutions segment. Growth was attributed to the acquisition of D&K Healthcare Resources, Inc. and organic growth among existing customers.
- Profitability Recovery: The company returned to profitability with $751 million in net income, compared to a $157 million loss in 2005. The 2005 loss was heavily impacted by a $1.2 billion pre-tax charge for securities litigation.
- Securities Litigation: In 2006, the company recorded a net pre-tax charge of $45 million related to securities litigation, a significant reduction from the $1.2 billion charge in 2005. The company paid approximately $960 million into an escrow account for the consolidated class action settlement.
- Margin Expansion: Gross profit margin increased 8 basis points to 4.39% in 2006. This improvement was driven by higher buy-side margins in the pharmaceutical segment due to revised distribution arrangements with manufacturers and increased antitrust settlement proceeds ($95 million in 2006 vs. $41 million in 2005).
- Acquisitions: Significant acquisitions included D&K Healthcare Resources ($479 million) and Medcon, Ltd. ($82 million) in 2006.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted the successful transition of distribution arrangements with pharmaceutical manufacturers, which reduced dependence on price increases and improved cash flow. The company expects to continue paying quarterly cash dividends.
Outlook: Specific 2007 financial guidance is referenced in a separate Form 8-K dated May 4, 2006. Management anticipates share-based compensation charges to increase in 2007 due to the adoption of SFAS No. 123(R).
Key Risks and Contingencies:
- Securities Litigation: While the primary consolidated action was settled, approximately 92 lawsuits remain pending. The company maintains a $1.014 billion accrual but notes that ultimate costs could impact earnings.
- Customer Concentration: Sales to the ten largest customers accounted for 53% of total consolidated revenues, with the largest customer (Caremark RX, Inc.) representing 11%. Defaults by these customers could materially impact financial condition.
- Regulatory Environment: The company faces risks from changing healthcare regulations, including the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and potential FDA regulation of software products as medical devices.
- Goodwill Impairment: With $1.718 billion in goodwill, the company is subject to impairment testing. Adverse changes in market conditions or loss of significant customers could trigger impairment charges.
Investor Verification Checklist
- Securities Litigation Resolution: Verify the final status of the remaining pending lawsuits and the adequacy of the $1.014 billion accrual.
- Customer Concentration: Monitor the financial health and purchasing volumes of the top 10 customers, particularly Caremark RX, Inc.
- Share-Based Compensation Impact: Assess the impact of SFAS No. 123(R) adoption in 2007 on future net income, estimated at an additional $0.05 to $0.07 per diluted share.
- Pharmaceutical Pricing Trends: Evaluate the sustainability of improved buy-side margins given manufacturer pricing strategies and generic drug availability.
- Acquisition Integration: Review the integration progress and financial performance of the D&K Healthcare Resources acquisition.